Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - journals.sagepub.com
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - research.uni-luebeck.de
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - … Advances in Medical …, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective:</jats: title>< jats: p> Evaluation of the efficacy and
safety of atezolizumab/bevacizumab in a real-world HCC cohort, including patients with …
safety of atezolizumab/bevacizumab in a real-world HCC cohort, including patients with …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
T de Castro, LS Jochheim, M Bathon… - … Advances in Medical …, 2022 - europepmc.org
Objective Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - search.ebscohost.com
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy–a real-world experience
T de Castro, L Jochheim, M Bathon… - Zeitschrift für …, 2022 - thieme-connect.com
Thieme E-Journals - Zeitschrift für Gastroenterologie / Abstract DE EN Home Products Journals
Books Book Series Service Library Service Help Contact Portal Zeitschrift für Gastroenterologie …
Books Book Series Service Library Service Help Contact Portal Zeitschrift für Gastroenterologie …
[HTML][HTML] Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world …
T de Castro, LS Jochheim, M Bathon… - … Advances in Medical …, 2022 - ncbi.nlm.nih.gov
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - epub.ub.uni-muenchen.de
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
T de Castro, LS Jochheim, M Bathon… - Therapeutic …, 2022 - research.uni-luebeck.de
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …
HCC cohort, including patients with impaired liver function and prior systemic therapy …